Future Direction for Cancer Registries

Similar documents
Cancer Outcomes and Services Dataset: Implications for clinical teams

Informatics in the new NHS : PHE and NCIN 9 months on. Nicky Coombes National Cancer Intelligence Network

Cancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012

COSD & Source of Referral

Using Cancer Registration and MDT Data to Provide Information on Recurrent and Metastatic Breast Cancer

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Understanding lymphoma: the importance of patient data

to improve the collection and publication of data on chemotherapy activity, outcomes and costs, the chemotherapy dataset will be introduced

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report

An Integrated National Strategy for Breast Cancer Audit. Martin Lee Gill Lawrence

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Understanding value across pathways of care

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2017 report Published XX June 2017

What do blood cancer patients want? (And what do we need and expect too?)

Top Regimens by Diagnostic Group. April July 2012

Staging Issues: Lung Cancer & Mesothelioma. Mick Peake Clinical Lead, NCIN Chair, Lung SSCRG

The National Cancer Dataset Initiative ddd CTYA SSCRG. Di Riley Associate Director for Clinical Outcomes

Apples and pears? A comparison of two sources of national lung cancer audit data in England

Identifying and counting people living with treatable but not curable cancer

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017

National Breast Cancer Audit next steps. Martin Lee

NLCA annual report analysis 2017 (for the population of 2016)

National Cancer Peer Review Programme

Cancer Services Performance Indicators. Data Collection Method 2014

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014

Haematological malignancies in England Cancers Diagnosed Haematological malignancies in England Cancers Diagnosed

Trust Board of Directors Public. Denise Gale. For Assurance and Information NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE

National Cancer Intelligence Network data usage. 17 November 2015 Veronique Poirier Principal Cancer Analyst NCIN

If unqualified, Complete remission is considered to be Haematological complete remission

Haemato-oncology Clinical Forum. 20 th June 2013

If unqualified, Complete remission is considered to be Haematological complete remission

National Bowel Cancer Audit

National Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns

National Cancer Intelligence Network Trends in incidence and outcome for haematological cancers in England:

Commissioning Chemotherapy Services Conference. Issues of consent in systemic therapy

Breast Screening Data Stephen Scott Head of Informatics LCA

Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand

Progress in improving cancer services and outcomes in England. Report. Department of Health, NHS England and Public Health England

REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2008

Data Definitions for the National Minimum Core Dataset to support the Introduction of Lymphoma Quality Performance Indicators

Ruth Howkins Deputy National Coordinator National Cancer Peer Review

Information Services Division NHS National Services Scotland

National Prostate Cancer Audit. Bill Cross June 2015

National Lung Cancer Audit outlier policy 2017

Data Definitions for the National Minimum Core Dataset to support the Introduction of Lymphoma Quality Performance Indicators

What are we aiming for?

Commissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013

Rare Urological Cancers Urological Cancers SSCRG

SACT: What can we learn from Real World Data? Dr Rebecca Smittenaar Analytical Lead (Systemic Anti-Cancer Therapy) Public Health England

Candidates must answer ALL questions

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator

What do we know about GBM Patient pathways in England?

Acute Oncology: Service Provision in Smaller Cancer Centres Ernie Marshall Clatterbridge Centre for Oncology

Achievements and Outcomes

Project Brief. New Cancer Waiting Times. Data Quality Assurance Audit

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

North Thames Children and Young People s Cancer Network

Upper GI Cancer Network Site-Specific Group. Work Programme/Service Delivery Plan 2011/14

Connecting Cancer Data to Clinical Outcomes Intelligence

Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:

Cancer Alliance Data Pack

RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY

GREATER MANCHESTER EXPERIENCE

Consultant-led Referral to Treatment (RTT) waiting times collection timetable: outcome of consultation

Asthma Audit Development Project: Hospital pilot information

Adult Acute leukemia. Matthew Seftel. August

Trust Guideline for the inclusion of women at High Risk of Breast Cancer in the NHS Breast Screening Programme

Meeting of the SWAG Network Haematology SSG

Dorset Cancer Alliance:

S E SCOTLAND CANCER NETWORK REPORT ON PROSPECTIVE AUDIT OF LYMPHOMA PATIENTS BORDERS, FIFE, AND LOTHIAN DIAGNOSED IN 2009

FGM Data Collection NHS Digital CAP

Cancer Alliance Data Pack

Wessex Cancer Alliance. Wessex Cancer Strategic Clinical Network

NCIN Conference Feedback 2015

Yorkshire Cancer Research Yorkshire Bowel Cancer initiative

Molecular Pathology Evaluation Panel and Molecular Pathology Consortium Advice Note

Cancer Waiting Times. 1 April Adjuvant Radical External Beam Radiotherapy Definitions. Version 1.0

National Cancer Patient Experience Survey Results. University Hospitals of Leicester NHS Trust. Published July 2016

Survival in Teenagers and Young. Adults with Cancer in the UK

National Cancer Patient Experience Survey Results. East Kent Hospitals University NHS Foundation Trust. Published July 2016

Vacancy list Pathway Boards

Cancer of Unknown Primary (CUP)

Blood Cancers in the Community

T his article is based on a recent report from

Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)

Information Services Division NHS National Services Scotland

The patient had a mild splenomegaly but no obvious lymph node enlargement. The consensus phenotype obtained from part one of the exercise was:

Aviva Group Protection Our guide to cancer

Richard Watson, Chief Transformation Officer. Dr P Holloway, GP Clinical Lead for Cancer Lisa Parrish, Senior Transformation Lead

WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

MDT IMPROVEMENT PROJECT. Professor Muntzer Mughal, UCLH

NATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit

Leukocytosis - Some Learning Points

Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Clinical Guidelines for Leukaemia and other Myeloid Disorders MDS

National Horizon Scanning Centre. Azacitidine (Vidaza) for myelodysplastic syndrome. September 2007

Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.

Transcription:

Future Direction for Cancer Registries Sally Vernon Head of Quality and Analysis Eastern Cancer Registry and Information Centre sally.vernon@ecric.nhs.uk

In Ye Olde Days. 8 regional cancer registries Variation in practice Different coding systems Different data sources Data hard to compare Difficulties of doing national work Duplications Timeliness Data comparability

One National Cancer Registration Service Solves these problems: Single England wide system Common standards and processes including data quality National datasets available for external analysis and research

One National Cancer Registration Service And takes us further! All systems development now done once instead of 8 times! Opportunity for all to reach standard of the best And to improve on that! COSD compliant Rapid processing of many data sources Direct feedback of data to clinical teams Support for (near) real-time surveillance, cancer audit and analysis

Data sources - patient-level data National Feeds Radiotherapy Data (RTDS) Chemotherapy Dataset (SACT) ONS - Cancer and noncancer deaths Cancer Waiting Times Data from MDT software systems Local Feeds Pathology full-text reports Local imaging systems Patient Administration Systems Cancer screening programmes - Bowel, Cervix and Breast National PET- CT imaging National cancer audits - Lung, Head and Neck, Upper GI and Colorectal Hospital Episode Statistics (HES) Encore Recurrent/Meta static Breast Audit Pilot CRUK Stratified Medicine (Sept 2011) Local clinical data systems National Pilots

Direct Provider data flows COSD TRUST DATAFLOWS NATIONAL REGISTRY DATABASE (COSD DATASET) KEY Trust Flows NO Trust Flows NO Trust Flows Trust Flows Trust Flows NATIONAL REGISTRY DATABASE (COSD DATASET) Trust Flows NO Trust Flows NO Trust Flows NO Trust Flows Data store Fully structured / coded N3 Network or other approved transmission medium Data flow HES extract Cancer Waits download Chemo summary Radiotherapy Summary ONS COSD Treatments Secondary Uses Service Open Exeter COSD Core and ALL Clinical COSD Path COSD Radiology Chemo Repository NatCanSAT Deaths Data Procedures / activity uploads Cancer Waits Upload SACT upload RTDS upload N3 Network or other approved transmission medium HOSPITAL PAS SYSTEM Cancer Services MDT System Laboratory system ` Radiology System E prescribing system Verify and Record Acute Trust / Cancer Centre

One National Cancer Registration Service To have: Single cancer registration service for England Near real-time comprehensive data collection and quality assurance For entire cancer pathway For all patients diagnosed and treated Providing: Near real-time feedback for providers and clinical teams (months not years) QA, completeness, clinical indicators, etc Stronger partnerships between Registries and Trusts Local data collection at MDTs is key to success

Information Governance S251 NHS Act exemption All cancer registries covered one annual application Annual renewal through National Information Governance Board (NIGB) and corresponding statutory instrument Caldicott Guardian sign-off required to allow transfer of data to and from organisations existing signoff covers COSD

Information Governance Data Protection Act All cancer registries are registered under the DPA. Fair processing notices, including rights to withdraw consent, are provided through the UKACR Patient Information Leaflet Leaflet available from: www.orderline.dh.gov.uk/ecom_dh/public/home.jsf ACR078 About Cancer Registration

Staging Completeness Focus on improving staging data quality In 2010, some registries staged over 70% of cases, others less than 30% Need to understand stage of disease to understand Appropriate treatments Expected outcomes Case mix adjust fairly Historically, registry data focussed on Lung, breast, colorectal

Staging Completeness It is possible to collect Ann Arbor staging data for lymphomas The Eastern Cancer Registry prioritised this as a valuable data item 86% with known stage for Non Hodgkin s 93% with known stage for Hodgkin s Not historically a priority in other areas of the country Now mandated by COSD should start to see national staging data.

Improved coding systems Currently variation in coding systems used to collect information on tumours One national system will see all tumours coded in ICD O3 This separates out coding for site and morphology Greatly improved lymphoma data not just it is a lymphoma but this is a lymphoma and this is where it is

Richer data from COSD Site specific fields Selected by the SSCRG who had to justify the value of each one Examples: Platelet count (for CML, CLL, Myeoldysplasia) White blood cell count (for AML, ALL, Hodgkin s) Hasford Index and Sokal Index (for CML) etc etc Will be collected and coded consistently around the country.

Feedback for Providers and Clinical Teams Monthly Conformance Report Extract files received, number of cases, timeliness etc Data Quality Initial completeness eg NHS number, stage Summary Information Indicators Eg COSD data item completeness Clinical and Performance Indicators NICE Quality Standards etc

Proposed Feedback Timetable First submission ~ March 13 First feedback reports ~ April 13 Standard clinical feedback reports ~ Mar 14 First data quality reports ~ Oct 13 Jan 14 July 13 SITE SPECIFIC CLINICAL SITE SPECIFIC PATHOLOGY JAN 15 FULL COSD DATASET submitted in XML Jan 13 CORE and SITE SPECIFIC STAGE July 12 ISN issued

Feedback Indicators?

Feedback Dashboards and profiles?

Feedback Patient Pathways?

Feedback Patient Pathways?

Feedback Interactive tools?

Feedback Direct querying?!

Future Feedback? No point providing feedback if no-one is reading it! Needs to be Easy to use Engaging Answering the questions clinicians, nurses and service managers care about! Important to work with the users to develop tools that are best for them Not necessarily one size fits all

Conclusions A single cancer registration system (ENCORE) for England COSD compliant Routine, timely feedback Provide powerful data for local, national and international analysis Any further questions, feel free to contact me sally.vernon@ecric.nhs.uk or the lead cancer registry for Haematology caroline.brook@nycris.leedsth.nhs.uk

Haematology Specific (1) Data Item Section HAEMATOLOGY - LABORATORY RESULTS HAEM ATOLOGY - LABORATORY RESULTS - CM L, CLL, M YELODYSPLASIA HAEM ATOLOGY - LABORATORY RESULTS - AM L, ALL, HODGKIN HAEM ATOLOGY - LABORATORY - HODGKIN, CLL, M YELODYSPLASIA, FOLLICULAR HAEM ATOLOGY - LABORATORY RESULTS - M YELODYSPLASIA HAEM ATOLOGY - LABORATORY RESULTS -M YELODYSPLASIA HAEM ATOLOGY - LABORATORY RESULTS - M YELODYSPLASIA HAEM ATOLOGY - LABORATORY RESULTS - M YELOM A, HODGKIN HAEM ATOLOGY - LABORATORY RESULTS - M YELOM A HAEM ATOLOGY - LABORATORY RESULTS - HODGKIN HAEM ATOLOGY - LABORATORY RESULTS - FOLLICULAR, DLBCL, OTHER LYM PHOM AS HAEM ATOLOGY - LABORATORY RESULTS - CLL HAEM ATOLOGY - LABORATORY RESULTS - CM L HAEM ATOLOGY - LABORATORY RESULTS - CM L HAEM ATOLOGY - LABORATORY RESULTS - AM L HAEMATOLOGY - CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - FOLLICULAR HAEM ATOLOGY - CANCER CARE PLAN - FOLLICULAR, DLBCL, OTHER LYM PHOM AS, HODGKIN HAEM ATOLOGY - CANCER CARE PLAN - DLBCL HAEMATOLOGY - CML CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - CM L HAEM ATOLOGY - CANCER CARE PLAN - CM L HAEM ATOLOGY - CANCER CARE PLAN - CM L Data Item Name PLATELET COUNT WHITE BLOOD CELL COUNT (HIGHEST PRE TREATMENT) BLOOD HAEMOGLOBIN CONCENTRATION BONE MARROW KARYOTYPE BONE MARROW BLASTS PERCENTAGE NEUTROPHIL COUNT ALBUMIN BETA2 MICROGLOBULIN LEVEL BLOOD LYMPHOCTYE COUNT LACTATE DEHYDROGENASE LEVEL BLOOD MYELOBLASTS PERCENTAGE BLOOD BASOPHILS PERCENTAGE BLOOD EOSINOPHILS PERCENTAGE CYTOGENETIC GROUP (ACUTE MYELOID LEUKAEMIA) NUMBER OF ABNORMAL NODAL AREAS PRIMARY EXTRANODAL SITE NUMBER OF EXTRANODAL SITES CODE SPLEEN CM BELOW COSTAL MARGIN HASFORD INDEX (CHRONIC MYELOID LEUKAEMIA) SOKAL INDEX (CHRONIC MYELOID LEUKAEMIA)

Haematology Specific (2) Data Item Section HAEMATOLOGY - MYELODYSPLASIA CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - M YELODYSPLASIA HAEMATOLOGY - CLL CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - CLL HAEM ATOLOGY - CANCER CARE PLAN - CLL HAEM ATOLOGY - CANCER CARE PLAN - CLL HAEM ATOLOGY - CANCER CARE PLAN - CLL HAEM ATOLOGY - CANCER CARE PLAN - CLL HAEMATOLOGY - FOLLICULAR CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - FOLLICULAR HAEMATOLOGY - DLBCL CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - DLBCL HAEMATOLOGY - MYELOMA CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - M YELOM A HAEMATOLOGY - HODGKIN CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - HODGKIN HAEMATOLOGY - ACUTE LYMPHOCYTIC LEUKAEMIA CANCER CARE PLAN HAEM ATOLOGY - CANCER CARE PLAN - ACUTE LYM PHOCYTIC LEUKAEM IA HAEMATOLOGY - STAGING HAEM ATOLOGY - STAGING - HODGKIN, FOLLICULAR, DLBCL, OTHER LYM PHOM AS HAEM ATOLOGY - STAGING - HODGKIN, FOLLICULAR, DLBCL, OTHER LYM PHOM AS HAEM ATOLOGY - STAGING - HODGKIN, FOLLICULAR, DLBCL, OTHER LYM PHOM AS HAEM ATOLOGY - STAGING - HODGKIN, FOLLICULAR, DLBCL, OTHER LYM PHOM AS Data Item Name IPSS (MYELODYSPLASIA) HEPATOMEGALY INDICATOR SPLENOMEGALY INDICATOR NUMBER OF LYMPHADENOPATHY AREAS RAI STAGE BINET STAGE FLIPI INDEX SCORE (R)IPI INDEX for DLBCL ISS STAGE for MYELOMA HASENCLEVER INDEX HASENCLEVER INDEX ANN ARBOR STAGE ANN ARBOR SYMPTOMS ANN ARBOR EXTRANODALITY ANN ARBOR BULK